Global Cancer Immunotherapies Market Forecasted To Hit $75.8 Billion In 2022 At Compound Annual Growth Rate Of 23.9%
The cancer immunotherapies market is forecast to rise from a value of $16.9 billion in 2015 to $75.8 billion in 2022, at a compound annual growth rate of 23.9%.
February 28, 2017 /MarketersMedia/ —
Global Cancer Immunotherapies Market to 2022 – Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market The cancer immunotherapies market is forecast to rise from a value of $16.9 billion in 2015 to $75.8 billion in 2022, at a compound annual growth rate of 23.9%. The cancer immunotherapies pipeline is vast, with a significant degree of diversity in terms of molecule types and targets. The company landscape is growing increasingly competitive.
Complete report on Global Cancer Immunotherapies Market to 2022 – Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market spread across 63 pages available at: http://www.reportsnreports.com/contacts/discount.aspx?name=799564
Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which includes breast cancer, melanoma, NSCLC and ovarian cancer.
• Cancer Immunotherapies Key Marketed Products
• Cancer Immunotherapies Pipeline Landscape Assessment
• Cancer Immunotherapies Multi-scenario Market Forecast to 2022
• Cancer Immunotherapies Company Analysis and Positioning
• Cancer Immunotherapies Strategic Consolidations
• Cancer Immunotherapies Market, Global, Epidemiology of Key Oncology Indications, 2016
• Cancer Immunotherapies Market, Global, Regional Lymph Node and Metastasis Staging,
• Cancer Immunotherapies Market, Global, Eastern Co-operative Oncology Group Criteria, 2016
• Cancer Immunotherapies Market, Global, Breast Cancer Histopathological and Molecular Classification, 2016
• Cancer Immunotherapies Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2016
• Cancer Immunotherapies Market, US, Ovarian Cancer Stage and Survival Rates (%), 2016
• Cancer Immunotherapies Market, US, Lung Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2016
• Cancer Immunotherapies Market, US, Ovarian Cancer Stage at Diagnosis and Five-year Relative Survival
Get Discount on Report at: http://www.reportsnreports.com/contacts/discount.aspx?name=799564
Companies Discussed In Report:
Celgene, Bristol-Myers Squibb, Roche , Merck & Co, AstraZeneca , Novartis , Amgen , Pfizer, Kite Pharma
Scope:
The cancer immunotherapies market already consists of some commercially successful products.
• Which classes of drug dominate the market?
• What additional benefits have newly approved therapies brought to the market?
The cancer immunotherapies pipeline is vast, with a significant degree of diversity in terms of molecule types and targets.
• Which molecular targets appear most frequently in the pipeline?
• What are the commercial prospects for the most promising late-stage pipeline products?
The cancer immunotherapies market is forecast to rise from a value of $16.9 billion in 2015 to $75.8 billion in 2022, at a compound annual growth rate of 23.9%.
• Which products are forecast to drive this substantial degree of growth?
• Will generic competition have a significant impact on the market over the forecast period?
The company landscape is growing increasingly competitive.
• What are the leading companies in terms of market share?
• Which companies are forecast to experience the greatest growth in market share?
• What are the drivers of growth for key companies in the market?
• How dependent are the key companies on this disease cluster for revenue?
• Which companies rely heavily on this disease cluster for revenue?
Get This Report at: http://www.reportsnreports.com/purchase.aspx?name=799564
Reasons to Buy
• Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which includes breast cancer, melanoma, NSCLC and ovarian cancer.
• Assess the current treatment landscape, with product profiles covering prominent marketed therapies, including revenue forecasts.
• Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
• Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
• Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from cancer immunotherapy products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
• Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals
About Us:
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Contact Info:
Name: Ritesh Tiwari
Email: sales@reportsandreports.com
Organization: ReportsandReports
Phone: + 1 888 391 5441
For more information, please visit http://www.reportsnreports.com/reports/799564-global-cancer-immunotherapies-market-to-2022-immune-checkpoint-inhibitors-and-therapeutic-cancer-vaccines-to-characterize-increasingly-competitive-market.html
Source: MarketersMedia
Release ID: 173794
Copyright © 1999-2013 SproutNews.com
